View this email as a web page

Sponsored Message:

Coverage for SCEMBLIX is expanding

Developed under the direction and sponsorship of Novartis Pharmaceuticals Corporation.

View this email in your browser

SCEMBLIX coverage just got even better!

The 3 largest PBMs cover SCEMBLIX in the 1st line with no steps^3,*

CVS Caremark Formularies

Express Scripts National Formularies

OptumRx National Formularies

*For private insurance patients.


	PA CONSISTENT WITH LABEL

	NO STEPS REQUIRED

77%	of SCEMBLIX claims resulted in $0 out-of-pocket for patients.^4,†,‡

^†	Reflects use of the $0 Co-Pay Plus program.
^‡	Across private insurance, Medicare, and Medicaid.

Click Here for YOUR Local Coverage Information

INDICATION

SCEMBLIX is indicated for the treatment of adult patients with:

•	Newly diagnosed Philadelphia chromosome‑positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)

◦	This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s)

IMPORTANT SAFETY INFORMATION

Myelosuppression

•	Thrombocytopenia, neutropenia, and anemia, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX

•	Perform complete blood counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression

•	Based on the severity of thrombocytopenia and/or neutropenia, reduce dose, temporarily withhold, or permanently discontinue SCEMBLIX as described in the prescribing information

Pancreatic Toxicity

•	Pancreatitis (including grade 3 reactions) and elevation in serum lipase and amylase (including grade 3/4 elevations), have occurred in patients receiving SCEMBLIX

•	Assess serum lipase and amylase levels monthly during treatment with SCEMBLIX, or as clinically indicated. Monitor patients for signs and symptoms of pancreatic toxicity. Perform more frequent monitoring in patients with a history of pancreatitis

•	If lipase and amylase elevation are accompanied by abdominal symptoms, temporarily withhold SCEMBLIX and consider appropriate diagnostic tests to exclude pancreatitis

•	Based on the severity of lipase and amylase elevation, reduce dose, temporarily withhold, or permanently discontinue SCEMBLIX as described in the prescribing information

Hypertension

•	Hypertension, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX

•	Monitor and manage hypertension using standard antihypertensive therapy during treatment with SCEMBLIX as clinically indicated

•	For grade 3 or higher reactions, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX as described in the prescribing information depending on persistence of hypertension

Hypersensitivity

•	Hypersensitivity, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX. Reactions included rash, edema, and bronchospasm

•	Monitor patients for signs and symptoms and initiate appropriate treatment as clinically indicated

•	For grade 3 or higher reactions, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX as described in the prescribing information depending on persistence of hypersensitivity

Cardiovascular Toxicity

•	Cardiovascular toxicity (including ischemic cardiac and central nervous system conditions; and arterial thrombotic and embolic conditions) and cardiac failure have occurred in patients receiving SCEMBLIX. Some toxicities were grade 3/4 and 5 fatalities were reported

•	Arrhythmia, including QTc prolongation, have occurred in patients receiving SCEMBLIX. Some of these arrhythmias were grade 3/4

•	Monitor patients with a history of cardiovascular risk factors for cardiovascular signs and symptoms. Initiate appropriate treatment as clinically indicated

•	For grade 3 or higher cardiovascular toxicity, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX as described in the prescribing information depending on persistence of cardiovascular toxicity

Embryo-Fetal Toxicity

•	SCEMBLIX can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus if SCEMBLIX is used during pregnancy or if the patient becomes pregnant while taking SCEMBLIX

•	Verify the pregnancy status of females of reproductive potential prior to starting treatment with SCEMBLIX. Advise females to use effective contraception during treatment and for at least 1 week after the last SCEMBLIX dose

ADVERSE REACTIONS

•	Most common adverse reactions (≥20%) were musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea

•

Most common select laboratory abnormalities (≥20%) were lymphocyte count decreased, leukocyte count decreased, platelet count decreased, neutrophil count decreased, calcium corrected decreased, lipase increased, cholesterol increased, uric acid increased, alanine aminotransferase increased, alkaline phosphatase increased, hemoglobin decreased, triglycerides increased, creatine kinase increased, amylase increased, and aspartate aminotransferase increased

DRUG INTERACTIONS

•	Asciminib is an inhibitor of CYP3A4, CYP2C9, P-gp, OATP1B, and BCRP. Asciminib is a CYP3A4 substrate

•	Closely monitor for adverse reactions during concomitant use of strong CYP3A4 inhibitors and SCEMBLIX at 200 mg twice daily

•	Avoid concomitant use of itraconazole oral solution containing hydroxypropyl‑β‑cyclodextrin and SCEMBLIX at all recommended doses

•	Closely monitor for adverse reactions during concomitant use of certain CYP3A4 substrates and SCEMBLIX at 80 mg total daily dose. Avoid use of SCEMBLIX at 200 mg twice daily

•

Avoid concomitant use of CYP2C9 substrates and SCEMBLIX at all recommended doses. If coadministration with 80 mg total daily dose is unavoidable, reduce the CYP2C9 substrate dosage as recommended in its prescribing information. If coadministration with 200 mg twice daily is unavoidable, consider alternative therapy with a non‑CYP2C9 substrate

•	Closely monitor for adverse reactions during concomitant use of certain P‑gp substrates and SCEMBLIX at all recommended doses

•	Avoid concomitant use of rosuvastatin or atorvastatin and SCEMBLIX at all recommended doses. Closely monitor for adverse reactions during concomitant use of other OATP1B or BCRP substrates and SCEMBLIX at all recommended doses

Click here for full Prescribing Information.

CML, chronic myeloid leukemia; NCCN, National Comprehensive Cancer Network; PA, prior authorization; PBM, pharmacy benefit manager; Ph+ CML‑CP, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

References: 1. Scemblix. Prescribing information. Novartis Pharmaceuticals Corp. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Chronic Myeloid Leukemia V.3.2025. ©National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 5, 2025. To view the most recent and complete version of the guidelines, go to NCCN.org . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Data on file. MMIT coverage lives data. Novartis Pharmaceuticals Corp; 2025. 4. Data on file. NPS analysis of IQVIA SCEMBLIX OOP landscape readout (full year 2023). Novartis Pharmaceuticals Corp; 2024.

This is a sponsored message from IQVIA on behalf of Novartis Pharmaceuticals Corporation. IQVIA provides sponsored health care‒related messages from trusted third parties. This material is intended specifically and exclusively for US health care professionals. You are receiving this email because you have subscribed and agreed to receive information from the IQVIA email list.

If you prefer not to receive these messages from this sender, for this brand, please click here and confirm your request. You may continue receiving emails from other Novartis brands.

IQVIA

102‌55 W. Higg‌ins Ro‌ad, Suite 280

Rose‌mont, I‌L 60‌018

IQVIA Privacy Policy

Novartis Pharmaceuticals Corporation

3/‌25

42‌59‌61

This content is sponsored by Novartis Pharmaceuticals Corporation, and ION Oncology Practice Network has not independently reviewed or verified the information provided by Novartis.

This email was sent to karleigh.bard-marsh@cencora.com because you have an account with or are a valued partner of Cencora Specialty GPOs | ION Oncology Practice Network. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.